VEGF inhibitors in -mutated lung cancer: a never-ending story?
作者信息
Alexander Mariam, Halmos Balazs
机构信息
Department of Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA.
出版信息
Ann Transl Med. 2018 Dec;6(23):446. doi: 10.21037/atm.2018.11.20.
Abstract
摘要
相似文献
1
VEGF inhibitors in -mutated lung cancer: a never-ending story?
Ann Transl Med. 2018 Dec;6(23):446. doi: 10.21037/atm.2018.11.20.
2
Combined Inhibition of EGFR and VEGF Pathways in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Curr Oncol Rep. 2020 Sep 18;22(12):119. doi: 10.1007/s11912-020-00981-0.
3
Epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with EGFR wild-type non-small-cell lung cancer: the never-ending story.
J Clin Oncol. 2013 Sep 10;31(26):3291-3. doi: 10.1200/JCO.2013.50.2617. Epub 2013 Aug 12.
4
EGFR, EGFR TKI, and EMSI: a never-ending story.
Transl Lung Cancer Res. 2014 Dec;3(6):365-7. doi: 10.3978/j.issn.2218-6751.2014.09.10.
5
Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.
Int J Cancer. 2021 Sep 1;149(5):1121-1128. doi: 10.1002/ijc.33677. Epub 2021 May 24.
6
Dual inhibition of EGFR‑VEGF: An effective approach to the treatment of advanced non‑small cell lung cancer with EGFR mutation (Review).
Int J Oncol. 2023 Feb;62(2). doi: 10.3892/ijo.2023.5474. Epub 2023 Jan 5.
7
Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy.
Eur J Cancer. 2023 Mar;181:53-61. doi: 10.1016/j.ejca.2022.12.010. Epub 2022 Dec 19.
8
The Story of Angiogenesis Inhibitors in Non-small-cell Lung Cancer: The Past, Present, and Future.
Clin Lung Cancer. 2020 Jul;21(4):308-313. doi: 10.1016/j.cllc.2020.02.024. Epub 2020 Mar 12.
9
Differences in and mutation spectra in lung adenocarcinoma of never and heavy smokers.
Oncol Lett. 2013 Nov;6(5):1207-1212. doi: 10.3892/ol.2013.1551. Epub 2013 Aug 29.
10
Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer.
Thorac Cancer. 2022 Feb;13(3):386-393. doi: 10.1111/1759-7714.14267. Epub 2021 Dec 13.
引用本文的文献
1
The Role of SCARA5 as a Potential Biomarker in Squamous Cell Carcinoma of the Lung.
Int J Mol Sci. 2024 Jul 4;25(13):7355. doi: 10.3390/ijms25137355.
2
THSD7A Positivity Predicts Poor Survival and Is Linked to High FAK Expression and FGFR1-Wildtype in Female Patients with Squamous Cell Carcinoma of the Lung.
Int J Mol Sci. 2023 Jun 26;24(13):10639. doi: 10.3390/ijms241310639.
3
Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies.
Cancers (Basel). 2022 Jul 8;14(14):3337. doi: 10.3390/cancers14143337.
4
Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.
Drugs. 2022 Apr;82(6):649-662. doi: 10.1007/s40265-022-01698-z. Epub 2022 Apr 12.
5
Baseline predictors of short-term visual outcomes after intravitreal conbercept injection for neovascular age-related macular degeneration.
Arq Bras Oftalmol. 2023 Mar-Apr;86(2):97-104. doi: 10.5935/0004-2749.20230018.
6
The expression of SOX9, Tiam1, and PTEN is correlated with angiogenesis and prognosis in gastric cancer.
Transl Cancer Res. 2020 Jun;9(6):3998-4004. doi: 10.21037/tcr-20-2071.
7
Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model.
Front Med (Lausanne). 2021 Dec 2;8:750132. doi: 10.3389/fmed.2021.750132. eCollection 2021.
8
Vitexin attenuates epithelial ovarian cancer cell viability and motility and carcinogenesis via p38 and ERK1/2 pathways related VEGFA.
Ann Transl Med. 2020 Sep;8(18):1139. doi: 10.21037/atm-20-5586.
9
Cost-effectiveness of intravitreal conbercept versus other treatments for wet age-related macular degeneration.
Ann Transl Med. 2020 Aug;8(15):939. doi: 10.21037/atm-20-1334.
10
miR-107 inhibited malignant biological behavior of non-small cell lung cancer cells by regulating the STK33/ERK signaling pathway and .
J Thorac Dis. 2020 Apr;12(4):1540-1551. doi: 10.21037/jtd.2020.03.103.
本文引用的文献
1
Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study.
Lung Cancer. 2021 Jan;151:20-24. doi: 10.1016/j.lungcan.2020.11.020. Epub 2020 Nov 20.
2
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive -mutant Non-small Cell Lung Cancer.
Clin Cancer Res. 2021 Feb 15;27(4):992-1002. doi: 10.1158/1078-0432.CCR-20-1690. Epub 2020 Oct 12.
3
Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study).
Cancer. 2018 Oct 1;124(19):3830-3838. doi: 10.1002/cncr.31678. Epub 2018 Sep 7.
4
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
J Clin Oncol. 2018 Aug 1;36(22):2244-2250. doi: 10.1200/JCO.2018.78.7994. Epub 2018 Jun 4.
5
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.
6
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
7
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
Clin Lung Cancer. 2018 May;19(3):213-220.e4. doi: 10.1016/j.cllc.2017.11.003. Epub 2017 Nov 21.
8
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
9
Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials.
Clin Lung Cancer. 2018 Jan;19(1):84-92. doi: 10.1016/j.cllc.2017.06.016. Epub 2017 Jul 6.
10
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
Lancet Respir Med. 2017 May;5(5):435-444. doi: 10.1016/S2213-2600(17)30129-7. Epub 2017 Apr 10.
Zotero 插件